PT-141 (bremelanotide) works through the central melanocortin system rather than the vascular pathway PDE-5 inhibitors target. Bremelanotide is FDA-approved under the brand name Vyleesi for one specific indication in premenopausal women; what we dispense is a compounded preparation, which is not FDA-approved, and use in men is off-label. Whether it is appropriate for you is a question for your prescriber.

Members raising libido concerns with a prescriber.

• Acts on desire pathways, not vascular ones
• Works centrally via melanocortin receptors
• Studied in both men and women
• Used as-needed, not daily

• A 12-week supply of compounded PT-141 (as-needed dosing)
• Insulin syringes (30G)
• Alcohol prep pads
• Protocol check-in at week 6

POSSIBLE SIDE EFFECTS

• Nausea (most common, dose-related)
• Facial flushing
• Headache
• Temporary rise in blood pressure
• Injection-site reactions
• Darkening of skin or freckles with frequent use

DO NOT USE IF

• Uncontrolled hypertension or known cardiovascular disease
• Pregnancy or breastfeeding
• History of melanoma or numerous atypical moles
• Concurrent use of nitrates

Not exhaustive and not medical advice. Talk to your own healthcare provider about your history and medications before starting.

Delivery

Subcutaneous

Cycle length

As-needed dosing · 12-week supply

Category

Sexual

Storage

Refrigerated 2–8°C · use within compounding date

Tested before release

Purity and potency

Cold-chain shipped from our licensed 503A pharmacy in temperature- controlled packaging. Free shipping on every cycle. Tracking available in your portal once your order ships.